Translate 
Abstract
Background and objectivesChronic kidney disease (CKD) is a progressive illness linked to higher rates of morbidity and death. One of the main causes of CKD is diabetes mellitus (DM), and oxidative stress is essential to the disease's development. It has been demonstrated that the natural antioxidant melatonin reduces inflammation and oxidative damage in renal tissues. Given the lack of robust evidence, this double-blind clinical trial sought to investigate the effects of melatonin supplementation on oxidative stress and inflammatory markers in diabetic CKD patients.Materials and methodsThis trial included 41 diabetic patients with CKD (stages 3–4) from Shariati Hospital, Tehran, Iran. For ten weeks, participants were randomized to receive either a placebo or 5 mg of melatonin twice a day. Baseline characteristics, dietary intake, physical activity, and anthropometric measurements were recorded. Oxidative stress (TAC, TOS, MDA) and inflammatory markers (IL-6, hs-CRP) were measured before and after the intervention. Statistical analysis was performed using SPSS, with significance set at p < 0.05.ResultsThe 10-week trial was completed by 41 participants in total, and no adverse effects were noted. Dietary intake, physical activity, and anthropometric parameters did not significantly differ between the melatonin and control groups in baseline characteristics. Melatonin supplementation decreased oxidative stress and inflammatory biomarkers, including hs-CRP, MDA, TOS, and IL-6. However, these changes were not statistically significant.ConclusionOur study showed that melatonin supplementation did not significantly affect oxidative stress or inflammatory markers, including TAC, TOS, MDA, IL-6, and hs-CRP, in diabetic patients with CKD. Despite a decrement in TOS, MDA, IL-6, and hs-CRP levels after 10 weeks, this was not statistically significant. Further studies with larger sample sizes, greater dosages, and longer follow-up periods are recommended.
Highlights
Chronic kidney disease (CKD) is one of the most prevalent medical conditions in the twenty-first century that arises from the progressive and irreversible destruction of renal nephrons quantity and function
Our study showed that melatonin supplementation did not significantly affect oxidative stress or inflammatory markers, including total antioxidant capacity (TAC), total oxidative stress (TOS), MDA, IL-6, and highly sensitive C reactive protein (hs-CRP), in diabetic patients with CKD
CKD is mostly associated with four major risk factors: polycystic kidney disease (PKD), glomerulonephritis, diabetes mellitus (DM), and hypertension (HTN) [2, 6, 7]
Summary
Chronic kidney disease (CKD) is one of the most prevalent medical conditions in the twenty-first century that arises from the progressive and irreversible destruction of renal nephrons quantity and function. The kidney transplant or dialysis is the last course of treatment for individuals whose GFR falls to less than 15 ml/min/ 1.73 m 2, indicating the end stage of the illness. We refer to this state as ESRD [1]. The likelihood of an early death in CKD patients is, far greater than progressing the condition to its terminal stage and developing ESRD [3, 4]. As the most prevalent cause of ESRD, have a 20–40% risk of developing CKD [2, 8]. One of the main causes of CKD is diabetes mellitus (DM), and oxidative stress is essential to the disease’s development. Given the lack of robust evidence, this double-blind clinical trial sought to investigate the effects of melatonin supplementation on oxidative stress and inflammatory markers in diabetic CKD patients
Sign-in/Register to view highlights & summary 
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
